Review
Open access
Sep 2026
Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?
The putative clinical relevance of fourth-generation EGFR TKIs for NSCLC patients needs to be defined, and many development hurdles need to be cleared before victory can be declared.
W. Dempke, K. Fenchel, Loretta Sullivan et al.
· Cancer Drug Resistance · 0 citations